Eli Lilly and Resilience Invest $750M to Boost US Drug Manufacturing

Key Facts

In a move reflecting the growing trend toward securing critical supply chains, Eli Lilly and Resilience have announced a substantial $750 million investment. This financial commitment is dedicated to boosting domestic pharmaceutical manufacturing capabilities within the United States. According to reports, the companies aim to increase production capacity and ensure supply chain security for the U.S. market.

This investment comes as major pharmaceutical firms prioritize domestic infrastructure to mitigate global disruptions. Per market data, Eli Lilly (LLY) shares closed at $1210.02 on July 29, 2026, after reaching an intraday high of $1229.19. Such significant capital expenditure signals long-term growth confidence and reinforces the company's position as a mega-cap leader in the pharma sector.

Traders should watch for price action around the recent trading range of $1204.80 to $1229.19, based on the close as of July 29, 2026. Looking at broader manufacturing health, recent data showed the U.S. Manufacturing PMI at 53.8 as of July 24, suggesting a supportive operational environment for the industrial expansion planned by Eli Lilly.